The prospective, two-arm, randomized, controlled, multicentric phase III RENESANS trial is designed to compare the efficacy and safety of neoadjuvant stereotactic radiosurgery (Neo-SRS) versus multi-fraction stereotactic radiosurgery (mfSRS) in patients with large brain metastases, with the primary objective of evaluating the incidence of central nervous system composite events.
Age ≥18 years.
At least one brain metastasis appropriate for resection and not previously treated with SRS.
Lesions ≥2.5 cm and ≤6 cm in largest dimension.
Index lesion(s) will be treated, as outlined in the treatment section of the protocol.
No resectable lesion ≥2.5 cm.
Unresectable >4 cm lesion.
Previous whole brain irradiation.
Progressive brain lesion treated with SRS.
Maciej Harat
Lead sponsor
Prof. Franciszek Lukaszczyk Memorial Oncology Center
Sponsor institution
Bydgoszcz University of Science and Technology
Collaborator